Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Personalized Neo-antigen Vaccine in Advanced Solid Tumors (NeoPepVac) (NeoPepVac)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03715985
Recruitment Status : Recruiting
First Posted : October 23, 2018
Last Update Posted : December 23, 2019
Sponsor:
Information provided by (Responsible Party):
Inge Marie Svane, Herlev Hospital

Tracking Information
First Submitted Date  ICMJE October 17, 2018
First Posted Date  ICMJE October 23, 2018
Last Update Posted Date December 23, 2019
Actual Study Start Date  ICMJE January 28, 2019
Estimated Primary Completion Date January 1, 2021   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: October 19, 2018)
Number and type of reported adverse events [ Time Frame: 0-100 weeks ]
The primary objective is to assess tolerability and safety of a personalized neo-antigen vaccine containing up to 15 peptides derived from somatic mutation of the individual patient's cancer, with CAF09b as adjuvant. The vaccine formulation will be administered in combination with an approved anti-PD-1 or anti-PD-L1 inhibitor to patients with advanced solid tumors. The endpoint is the characterization of adverse events (AE) assessed by CTCAE 4.0.
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: October 19, 2018)
Treatment related immune responses [ Time Frame: 0-100 weeks ]
To evaluate the immunological impact of the treatment. Elispot and tetramer staining methods will be applied to identify NeoPepVac specific T cells in the blood over time
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures
 (submitted: October 19, 2018)
  • Overall survival [ Time Frame: 3 years ]
    Overall survival (OS), defined as the time from the start of treatment to death, will be described with the Kaplan-Meier curve.
  • Objective response rate Progression free survival [ Time Frame: 3 years ]
    Progression-free survival (PFS), defined as the time from start of treatment to disease progression, relapse or death due to any cause, whichever is earlier, will be described with the Kaplan-Meier curve.
  • Objective response rate [ Time Frame: 3 years ]
    Tumor responses will be evaluated using RECIST1.1 for the assessment of efficacy.
Original Other Pre-specified Outcome Measures Same as current
 
Descriptive Information
Brief Title  ICMJE Personalized Neo-antigen Vaccine in Advanced Solid Tumors (NeoPepVac)
Official Title  ICMJE A Pilot Study of the Safety, Tolerability, Feasibility and Efficacy of Anti-PD-1 or Anti-PD-L1 in Combination With a Personalized Neo-antigen Vaccine in Advanced Solid Tumors (NeoPepVac)
Brief Summary

The primary objective is to assess tolerability and safety of a personalized neo-antigen vaccine containing up to 15 peptides derived from somatic mutation of the individual patient's cancer, with CAF09b as adjuvant. The vaccine formulation will be administered in combination with an approved anti-PD-1 or anti-PD-L1 inhibitor to patients with advanced solid tumors. The endpoint is the characterization of adverse events (AE) assessed by CTCAE 4.0.

The secondary objective is feasibility to manufacture a personalized neo-antigen vaccine within 6 weeks of enrolment with the PIONEER pipeline, and to evaluate the immune response before, during and after treatment with the personalized neo-antigen vaccine. The endpoint is to evaluate the induction of adaptive immune responses to the personalized neo-antigen vaccine measured by functional assays and peptide-MHC multimer stainings.

The tertiary objective is to evaluate the clinical efficacy of the treatment. The endpoints will be objective responses (OR), progression free survival (PFS) and overall survival (OS).

Detailed Description

Cancer immunotherapy has shown the ability to improve the survival of patients with multiple types of advanced cancers. The human immune system can recognize the products of somatic genetic alterations in tumors, or neo-antigens, which are not expressed on normal cells. These neoantigens are an attractive immune target because their selective expression on tumors can minimize immune tolerance as well as the risk of side effects such as autoimmune reaction.

Although neoantigens are ideal targets for cancer immunotherapies, most neoantigens arise from unique mutations and are not shared between individual patients. Thus, neoantigen-directed immunotherapy will need to be personalized. Novel technical advances in next-generation sequencing allow fast and systematic prediction of cancer neoantigens for each individual patient. Initial attempts of therapeutic cancer vaccination targeting individual neo-antigens have proven non-toxic and met their immunological endpoints.

In this study investigators will use the proprietary platform PIONEER for fast and accurate identification of a neo-antigen vaccine tailored to each individual patient. The vaccine, based on 5-15 peptides derived from a patient's tumor individual neo-antigens, will be formulated with a novel adjuvant to strengthen CD8+ T cell immunity to cancer. Immune checkpoint inhibitors targeting PD-1 or PD-L1 will be administered both before, during and after vaccination to unleash the activity of vaccine-induced immune responses.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Study Design  ICMJE Intervention Model: Sequential Assignment
Intervention Model Description:
Not a randomized study. 25 patients to be included. Group A) has not yet started standard treatment Group B) has begun standard treatment at least 4 months before first vaccine, and the decease development is status quo.
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE
  • Malignant Melanoma, Metastatic
  • Non Small Cell Lung Cancer Metastatic
  • Kidney Cancer Metastatic
Intervention  ICMJE Drug: EVAX-01-CAF09b
The personalised NPV-ds001 drug substance consists of multiple linear peptides (Pep-Ints) comprising natural L-amino acids dissolved in Dimethyl sulfoxide (DMSO) and 1 ml adjuvants (CAF09b) and 1,08 ml Tris buffer (25 ml).
Other Name: NPV-ds001-CAF09b
Study Arms  ICMJE Experimental: NeoPepVac
Group A (has not yet started standard treatment) and Group B (has begun standard treatment at least 4 months before first vaccine, and the decease development is status quo) will receive 6 vaccines in total. Firstly 3 vaccines intraperitoneal biweekly and lastly 3 vaccines intramuscular biweekly while the patients are receiving standard immune therapy.
Intervention: Drug: EVAX-01-CAF09b
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: October 19, 2018)
25
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE January 1, 2022
Estimated Primary Completion Date January 1, 2021   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Target Disease Exception

    1. The subject must sign and date the IRB/IEC approved written informed consent form prior to the performance of any study-related procedures that are not considered part of standard of care.
    2. Consent for tumor biopsy samples. i. Subject must consent and will be required to undergo a MANDATORY pre-treatment biopsy; therefore, subjects must have a lesion located such that the specimen can be obtained at acceptable clinical risk as judged by the Investigator. The acquisition of existing formalin-fixed paraffin-embedded (FFPE) tumor tissue, either a block or unstained slides, for performance of correlative studies should also be collected if available. Subjects unable to provide a pre-treatment tumor biopsy or do not have accessible lesions are not eligible. If there is only one measurable lesion, and a core-needle biopsy is done (instead of excisional), the lesion may be used as measurable lesion. If there are more than one measurable lesions, the lesion being biopsied should not be a target lesion. Subjects must have histologic or cytologic confirmation of an incurable solid malignancy that is advanced (metastatic and/or unresectable)

      2. Target population

    a) Subjects must have cytologic or histologic confirmation of one of the following selected advanced (metastatic and/or unresectable) solid malignancies: i. Malignant melanoma - Uveal melanoma is NOT eligible ii. Non-small cell lung cancer: squamous or non-squamous histology iii. Bladder carcinoma: transitional cell carcinoma of the urothelium involving the bladder, urethra, ureter, or renal pelvis.

    b) Subjects must fall into one of these two categories: i. Cohort A (limited to max 15 subjects): candidate to treatment with one anti-PD-1 or anti-PD-L1 agent but who had not previously been treated with anti-PD-1 or anti-PD-L1 in the metastatic/unresectable setting.

    ii. Cohort B (limited to max 15 subjects): subjects who are treated continuously for at least 4 months with one anti-PD-1 or anti-PD-L1 agent in the metastatic/unresectable setting, without unequivocal objective response or disease progression, and who qualify for continued treatment with the same agent, who accept a second biopsy.

    c) At least one measurable parameter according to RECIST 1.1.

    d) ECOG performance status of 0 or 1

    e) Life expectancy of >12 weeks at the time of informed consent per Investigator assessment

    f) Adequate organ function as defined by the following hematological and biochemical criteria:

    a. AST and ALT ≤2,5 X ULN or ≤5 X ULN with liver metastases b. Serum total bilirubin ≤1,5 X ULN or direct bilirubin ≤ ULN for patient with total bilirubin level > 1,5 ULN c. Serum creatinine ≤1,5 X ULN d. ANC (Absolute Neutrophil Count) ≥1,000/mcL e. Platelets ≥ 75,000 /mcL f. Hemoglobin ≥ 9 g/dL eller ≥ 5.6 mmol/L

3. Age and reproductive status:

  1. Age ≥ 18
  2. Women must not be breastfeeding
  3. Women of childbearing potential: a negative pregnancy test is mandatory within 72 hours prior to the start of study drug
  4. Woman: Agree to use contraceptive methods with a failure rate of < 1 % per year during the treatment period and for at least 150 days after the study treatment. Safe contraceptive methods for women are birth control pills, intrauterine device, contraceptive injection, contraceptive implant, contraceptive patch or contraceptive vaginal ring.
  5. Men: if sexually active with women of childbearing potential, agree to use contraceptive measures; agree to refrain from donating sperm

Exclusion Criteria:

  1. Target Disease Exception

    a) Subjects with known or suspected CNS metastases or with the CNS as the only site of active disease are excluded with the following exceptions: i. Subjects with controlled brain metastases will be allowed to enroll. Controlled brain metastases are defined as those with no radiographic progression for at least 4 weeks after radiation and/or surgical treatment at the time of consent. Subjects must have been off of steroids for at least 2 weeks prior to informed consent, and have no new or progressive neurological signs and symptoms.

  2. Medical History and Concurrent Diseases

    1. Subjects with an active, known or suspected autoimmune disease. Subjects with type I diabetes mellitus, hypothyroidism only requiring hormone replacement, skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll.
    2. Prior malignancy active within the previous 3 years except for locally curable cancers that have been apparently cured, such as basal or squamous cell skin cancer, or carcinoma in situ of the prostate, cervix, or breast.
    3. A known or underlying medical condition that, in the opinion of the Investigator or Sponsor, could make the administration of study drug hazardous to the subject or could adversely affect the ability of the subject to comply with or tolerate study
    4. Requirement for daily supplemental oxygen
    5. The patient has a history of pneumonitis, organ transplant, human immunodeficiency virus positive, active hepatitis B or hepatitis C
    6. Any of the following medications or procedures:

    i. Within 2 weeks prior to time of treatment initiation: I. Systemic or topical corticosteroids at immunosuppressive doses (> 10 mg/day of prednisone or equivalent). Inhaled or topical steroids, and adrenal replacement steroid doses > 10 mg daily prednisone equivalent, are permitted in the absence of active autoimmune disease.

    II. Palliative radiation or gamma knife radiosurgery ii. Within 4 weeks prior to time of treatment initiation: I. Any anticancer drug II. Any vaccine or adjuvant III. Allergen hyposensitization therapy IV. Growth factors V. Major surgery, or the subject has not recovered from surgery at the time of treatment initiation

    g) The subject has not recovered to grade 0-1 from adverse events due to prior chemotherapy, radioactive or biological cancer therapy

    h) History of life-threatening or severe immune related adverse events on treatment with another immunotherapy and is considered to be at risk of not recovering

    i) The subject is expected to require any other form of systemic antineoplastic therapy while receiving the treatment

    j) Any condition that will interfere with patient compliance or safety (including but not limited to psychiatric or substance abuse disorders)

    k) Known, suspected or anticipated side effects to vaccine adjuvants

    l) Significant medical disorder according to investigator; e.g. severe asthma or chronic obstructive lung disease, dysregulated heart disease or dysregulated diabetes mellitus

    m) Concurrent treatment with other experimental drugs

    n) Severe allergy or anaphylactic reactions earlier in life

  3. Other exclusion criteria

    1. The patient is unable to voluntarily agree to participate
    2. Prisoners or subjects who are involuntarily incarcerated
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 120 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Sofie K Moerk, MD +4538682980 sofie.kirial.moerk@regionh.dk
Contact: Inge Marie Svane, Prof., MD +4538683868 inge.marie.svane@regionh.dk
Listed Location Countries  ICMJE Denmark
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03715985
Other Study ID Numbers  ICMJE AA1833
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: Undecided
Responsible Party Inge Marie Svane, Herlev Hospital
Study Sponsor  ICMJE Herlev Hospital
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Principal Investigator: Inge Marie Svane, Prof., MD CCIT (Center for Cancer Immune Therapy)
PRS Account Herlev Hospital
Verification Date December 2019

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP